Pyxis Oncology (PYXS)
NASDAQ:PYXS
PYXS Stock Chart & Stats
$1.43
-$0.10(-5.75%)
At close: 4:00 PM EST
$1.43
-$0.10(-5.75%)
Day’s Range― - ―
52-Week Range$0.83 - $5.55
Previous CloseN/A
Volume258.73K
Average Volume (3M)757.02K
Market Cap
$87.34M
Enterprise Value$90.59M
Total Cash (Recent Filing)$66.86M
Total Debt (Recent Filing)$18.67M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
May 08, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding62,831,245
10 Day Avg. Volume789,983
30 Day Avg. Volume757,017
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.34
Price to Sales (P/S)5.16
P/FCF Ratio-1.13
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue6.54
Enterprise Value/Gross Profit6.34
Enterprise Value/Ebitda-1.13
Forecast
1Y Price Target
$6.25Price Target Upside337.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.3
Revenue Forecast (FY)$58.33K
Bulls Say, Bears Say
Bulls Say
Clinical EnrollmentCompletion of enrollment in the Phase I monotherapy dose-expansion study for MICVO in recurrent/metastatic head and neck cancer creates a full patient cohort for updated efficacy and safety readouts that could influence investor sentiment.
Combination Therapy PotentialUpdated data from the MICVO plus pembrolizumab combination trial could demonstrate activity in earlier treatment lines and strengthen the asset's attractiveness to partners or acquirers.
Regulatory GuidanceFeedback from the U.S. Food and Drug Administration on the pivotal trial design for MICVO monotherapy in second-line or later head and neck cancer clarifies expectations for a registrational study and reduces regulatory uncertainty.
Bears Say
Financing And Liquidity RiskLimited cash reserves relative to the company's cash burn create funding risk that may necessitate dilutive financing or strategic partnerships to sustain the clinical program.
Pharmacokinetics And Dosing ComplexityPharmacokinetic modeling indicating higher drug exposure in heavier patients with current weight-based dosing points to a need for dosing strategy changes, increasing clinical development complexity.
Safety ConcernsPatient discontinuations tied to overexposure in heavier individuals highlight a safety issue that could complicate dose selection and the overall risk-benefit assessment.
Pyxis Oncology News
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $0.83 and its highest was $5.55 in the past 12 months.
What is Pyxis Oncology’s market cap?
Pyxis Oncology’s market cap is $87.34M.
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is May 08, 2026 which is in 42 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on Mar 23, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.344 by $0.064.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -0.37.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 62,831,245 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.344. Following the earnings report the stock price went down -3.401%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Currently, no hedge funds are holding shares in PYXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pyxis Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.25 (337.06% Upside)
$6.25 (337.06% Upside)
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.23%
12-Months-Change
Fundamentals
Return on Equity
-87.28%
Trailing 12-Months
Asset Growth
-45.93%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
PYXS Stock 12 Month Forecast
Average Price Target
$6.25
▲(337.06% Upside)
Technical Analysis
Nkarta
―
Greenwich LifeSciences
―
Elicio Therapeutics
―
Biomea Fusion
―
Nuvectis Pharma
―
Ownership Overview
10.26% Insiders
4.24% Mutual Funds
32.83% Other Institutional Investors
48.62% Public Companies and
Individual Investors